Condition

Metastatic Castration Sensitive Prostate Cancer (mCSPC)

ClinicalTrials.gov condition label

Clinical trials4

Recruiting1

Common interventions15

Lead sponsors shown1

Clinical trials

4 shown

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28

A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)NCT07779590 · 2026-08-19

ACTIVE_NOT_RECRUITING

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)NCT07086651 · 2025-07-21

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13

Common interventions

EnzalutamideDRUG3 apalutamideDRUG2 abirateroneDRUG1 cabazitaxelDRUG1 darolutamide plus androgen deprivation therapyDRUG1 degarelixDRUG1 docetaxelDRUG1 Enzalutamide plus androgen deprivation therapyDRUG1 goserelinDRUG1 leuprorelinDRUG1 Lutetium-177DRUG1 MevrometostatDRUG1 PlaceboDRUG1 Radium-223DRUG1 triptorelinDRUG1

Leading sponsors

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.